KLF2 and neoplasm: To determine the contribution of adaptive CD4+ and CD8+ T cell responses to KLF2 siRNA mediated antitumor immunity, GVAX vaccinated mice treated with 4-1BB-Ctrl or 4-1BB-KLF2 siRNA were depleted of CD4 or CD8 cells and monitored for tumor progression (Extended Data Fig. 3a & 3c) and survival (Extended Data Fig.3b & 3d).